Scope Biosciences

Executive Summary

Scope Biosciences, founded in 2019 and headquartered in Wageningen, Netherlands, is an agricultural biotechnology company leveraging proprietary CRISPR-Cas technology to develop rapid, on-site molecular diagnostic tests for plant pathogens. The company's core innovation lies in its CRISPR-based detection platform, which enables farmers and agronomists to identify diseases at the point of care within hours, rather than days, significantly reducing crop losses and improving yield. By focusing on speed, accuracy, and ease of use, Scope aims to empower growers with real-time data to make informed decisions, ultimately contributing to more sustainable and resilient food systems. The company operates in the growing precision agriculture diagnostics market, where early detection of pathogens like fungi, bacteria, and viruses is critical for effective disease management. With a strong IP portfolio and a clear value proposition, Scope is well-positioned to disrupt traditional laboratory-based testing methods. The management team combines deep expertise in CRISPR biology, plant pathology, and agribusiness, positioning the company for commercial traction in the near term. As food security concerns rise globally, Scope's technology offers a scalable solution to reduce reliance on pesticides and prevent widespread crop outbreaks, making it an attractive investment in the agri-tech space.

Upcoming Catalysts (preview)

• Q2 2027Commercial launch of first CRISPR-based diagnostic test for a major crop pathogen60% success
• H1 2027Strategic partnership or licensing deal with a leading agricultural input company55% success
• Q4 2026Series A or B funding round to scale manufacturing and expand product pipeline70% success